IL2RB and neoplasm: The IL2RB-biased engineered cytokine NKTR-214 significantly increases the ratio of CD8 CTLs to immunosuppressive CD4 FOXP3 T-regulatory cells, creating a potent anti-tumor environment, while also increasing the expression of immune-checkpoints such as CD274 (PDL1) (18).